{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:23:47Z","timestamp":1787761427321,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12072-026-11093-5","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:23:48Z","timestamp":1780053828000},"page":"1138-1149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial"],"prefix":"10.1007","volume":"20","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiguo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunliang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingji","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-8890","authenticated-orcid":false,"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"11","key":"11093_CR1","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.14309\/ajg.0000000000000786","volume":"115","author":"JJ Alukal","year":"2020","unstructured":"Alukal JJ, John S, Thuluvath PJ. Hyponatremia in cirrhosis: an update. Am J Gastroenterol. 2020;115(11):1775\u20131785","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"11093_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cld.2022.01.001","volume":"26","author":"H Rondon-Berrios","year":"2022","unstructured":"Rondon-Berrios H, Velez JCQ. Hyponatremia in cirrhosis. Clin Liver Dis. 2022;26(2):149\u2013164","journal-title":"Clin Liver Dis"},{"key":"11093_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u2013867","journal-title":"J Pharmacol Exp Ther"},{"key":"11093_CR4","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u20132112","journal-title":"N Engl J Med"},{"key":"11093_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jhep.2011.08.020","volume":"56","author":"A C\u00e1rdenas","year":"2012","unstructured":"C\u00e1rdenas A, Gin\u00e8s P, Marotta P, Czerwiec F, Oyuang J, Guevara M, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56:571\u2013578","journal-title":"J Hepatol"},{"key":"11093_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2009080857","volume":"21","author":"T Berl","year":"2010","unstructured":"Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21:705\u2013712","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"11093_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/hepr.12098","volume":"44","author":"I Sakaida","year":"2014","unstructured":"Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44(1):73\u201382","journal-title":"Hepatol Res"},{"issue":"17","key":"11093_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.2169\/internalmedicine.0629-17","volume":"57","author":"M Hayashi","year":"2018","unstructured":"Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Association between the serum sodium levels and the response to Tolvaptan in liver cirrhosis patients with ascites and hyponatremia. Intern Med. 2018;57(17):2451\u20132458","journal-title":"Intern Med"},{"issue":"8","key":"11093_CR9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00535-020-01691-x","volume":"55","author":"I Sakaida","year":"2020","unstructured":"Sakaida I, Terai S, Kurosaki M, Okada M, Hirano T, Fukuta Y. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). J Gastroenterol. 2020;55(8):800\u2013810","journal-title":"J Gastroenterol"},{"issue":"10","key":"11093_CR10","first-page":"936","volume":"39","author":"L Li","year":"2011","unstructured":"Li L, Bai H, Zhu WL. Tolvaptan therapy in hyponatremia with heart failure collaborative group. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(10):936\u2013940","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"12","key":"11093_CR11","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/jcph.342","volume":"54","author":"S Chen","year":"2014","unstructured":"Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, et al. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. J Clin Pharmacol. 2014;54(12):1362\u20131367","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"11093_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0399-8320(07)89420-6","volume":"31","author":"H Fontaine","year":"2007","unstructured":"Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol. 2007;31(5):504\u2013509","journal-title":"Gastroenterol Clin Biol"},{"issue":"1","key":"11093_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5604\/16652681.1226823","volume":"16","author":"JD Jia","year":"2017","unstructured":"Jia JD, Xie W, Ding HG, Mao H, Guo H, Li Y, et al. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: a prospective cohort study. Ann Hepatol. 2017;16(1):123\u2013132","journal-title":"Ann Hepatol"},{"issue":"32","key":"11093_CR14","doi-asserted-by":"publisher","first-page":"11400","DOI":"10.3748\/wjg.v20.i32.11400","volume":"20","author":"X Zhang","year":"2014","unstructured":"Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol. 2014;20(32):11400\u201311405","journal-title":"World J Gastroenterol"},{"key":"11093_CR15","doi-asserted-by":"publisher","first-page":"1324299","DOI":"10.3389\/fphar.2024.1324299","volume":"15","author":"H Liu","year":"2024","unstructured":"Liu H, Wang Y, Liu T, Chen Y, Zheng X, Liu M, et al. Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis. Front Pharmacol. 2024;15:1324299","journal-title":"Front Pharmacol"},{"issue":"3","key":"11093_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/1751-2980.12583","volume":"19","author":"YF Wang","year":"2018","unstructured":"Wang YF, Tang JT, Han T, Ding HG, Ye WJ, Wang MR, et al. Tolvaptan in Chinese cirrhotic patients with ascites: a randomized, placebo-controlled phase 2 trial. J Dig Dis. 2018;19(3):144\u2013154","journal-title":"J Dig Dis"},{"issue":"1","key":"11093_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12876-020-01536-0","volume":"20","author":"J Tang","year":"2020","unstructured":"Tang J, Wang Y, Han T, Mao Q, Cheng J, Ding H, et al. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterol. 2020;20(1):391","journal-title":"BMC Gastroenterol"},{"issue":"25","key":"11093_CR18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u20132418","journal-title":"N Engl J Med"},{"issue":"20","key":"11093_CR19","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u20131942","journal-title":"N Engl J Med"},{"issue":"1","key":"11093_CR20","first-page":"96","volume":"14","author":"X Xu","year":"2026","unstructured":"Xu X, Ding H, You H, Guan Y, Xu J, Li W, et al. Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025). J Clin Transl Hepatol. 2026;14(1):96\u2013115","journal-title":"J Clin Transl Hepatol"},{"issue":"7","key":"11093_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/hepr.13678","volume":"51","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51(7):725\u2013749","journal-title":"Hepatol Res"},{"issue":"2","key":"11093_CR22","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.31884","volume":"74","author":"SW Biggins","year":"2021","unstructured":"Biggins SW, Angeli P, Garcia-Tsao G, Gin\u00e8s P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;74(2):1014\u20131048","journal-title":"Hepatology"},{"issue":"1","key":"11093_CR23","first-page":"30","volume":"21","author":"H Kawaratani","year":"2021","unstructured":"Kawaratani H, Moriya K, Namisaki T, Shimozato N, Kaji K, Takaya H, et al. Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. Exp Ther Med. 2021;21(1):30","journal-title":"Exp Ther Med"},{"issue":"1","key":"11093_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12876-018-0857-0","volume":"18","author":"S Wang","year":"2018","unstructured":"Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, et al. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol. 2018;18(1):137","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"11093_CR25","doi-asserted-by":"publisher","first-page":"874","DOI":"10.7150\/ijms.41454","volume":"17","author":"K Kanayama","year":"2020","unstructured":"Kanayama K, Chiba T, Kobayashi K, Koroki K, Maruta S, Kanzaki H, et al. Long-term administration of tolvaptan to patients with decompensated cirrhosis. Int J Med Sci. 2020;17(7):874\u2013880","journal-title":"Int J Med Sci"},{"issue":"4","key":"11093_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1159\/000489258","volume":"36","author":"K Tajiri","year":"2018","unstructured":"Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, et al. Survival benefit of tolvaptan for refractory ascites in patients with advanced cirrhosis. Dig Dis. 2018;36(4):314\u2013321","journal-title":"Dig Dis"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11093-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11093-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11093-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:41:02Z","timestamp":1787758862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11093-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11093"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11093-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest related to the submission of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}